{"id":104,"date":"2026-07-13T20:23:55","date_gmt":"2026-07-13T20:23:55","guid":{"rendered":"https:\/\/dentaltransitions.sites.aigrowthagent.co\/compare-dso-offers-california-dental\/"},"modified":"2026-07-14T05:46:59","modified_gmt":"2026-07-14T05:46:59","slug":"compare-dso-offers-california-dental","status":"publish","type":"post","link":"https:\/\/dentaltransitions.com\/articles\/compare-dso-offers-california-dental\/","title":{"rendered":"How to Compare DSO Offers for Your California Practice"},"content":{"rendered":"<h2>Key Takeaways for California Dentists<\/h2>\n<ul>\n<li>\n<p>DSO negotiations are asymmetric because buyers negotiate weekly while most owners sell once. Without a structured comparison, many dentists leave hundreds of thousands of dollars on the table.<\/p>\n<\/li>\n<li>\n<p>Opening offers typically run below best-and-final. Accepting without an independent valuation or competitive bidding process can forfeit significant value.<\/p>\n<\/li>\n<li>\n<p>A diligence-grade EBITDA analysis built by a CPA, not buyer estimates, can be the foundation for defending valuation through diligence and reducing post-LOI renegotiation risk.<\/p>\n<\/li>\n<li>\n<p>McLerran &amp; Associates can provide side-by-side valuation and cash-flow modeling. <a target=\"_blank\" rel=\"noopener noreferrer nofollow\" href=\"https:\/\/dentaltransitions.com\/contact-us\/\"><strong>Schedule a free, confidential discovery call<\/strong><\/a> before responding to any offer.<\/p>\n<\/li>\n<\/ul>\n<h2>Core Deal Terms Every California Dentist Should Know<\/h2>\n<p>Before comparing offers, owners benefit from understanding a few core terms in plain language.<\/p>\n<ul>\n<li>\n<p><strong>EBITDA<\/strong> \u2013 Earnings Before Interest, Taxes, Depreciation, and Amortization. This is the profitability metric DSOs use to value practices. \u201cAdjusted\u201d or \u201cnormalized\u201d EBITDA adds back personal, discretionary, and one-time expenses to show the practice\u2019s true earning power.<\/p>\n<\/li>\n<li>\n<p><strong>LOI<\/strong> \u2013 Letter of Intent. This non-binding document outlines the key deal terms before a formal purchase agreement is drafted. Most real economic negotiation happens at this stage.<\/p>\n<\/li>\n<li>\n<p><strong>Diligence<\/strong> \u2013 The buyer\u2019s formal review of the practice\u2019s financials, operations, and legal standing after the LOI is signed. Weak valuations often get re-traded, meaning price and terms can be pushed down here.<\/p>\n<\/li>\n<li>\n<p><strong>Equity rollover<\/strong> \u2013 The portion of proceeds that stays invested as ownership in the DSO platform instead of being paid in cash. This stake is illiquid until the DSO recapitalizes or sells, often 3\u20137 years later.<\/p>\n<\/li>\n<li>\n<p><strong>Earnout<\/strong> \u2013 A contingent payment tied to post-close performance targets such as EBITDA, collections, or associate retention. Earnouts are not guaranteed and depend on future results.<\/p>\n<\/li>\n<li>\n<p><strong>Recapitalization<\/strong> \u2013 When a DSO\u2019s private equity backer sells or refinances the platform, creating a liquidity event for equity holders. This is usually when rollover equity converts to cash.<\/p>\n<\/li>\n<\/ul>\n<h2>Step 1: Build Complete Financials and a Diligence-Grade EBITDA<\/h2>\n<p>A defensible EBITDA number built by a CPA gives you a solid foundation for any comparison. This number should not come from a quick buyer estimate.<\/p>\n<figure style=\"text-align: center;\"><img src=\"https:\/\/cdn.aigrowthmarketer.co\/1782231605342-03c5ed4725a3.jpeg\" alt=\"At McLerran &amp; Associates, every engagement is built on an ironclad, CPA-led EBITDA analysis and practice valuation.\" style=\"max-height: 500px;\" loading=\"lazy\" decoding=\"async\"><figcaption><em>At McLerran &amp; Associates, every engagement is built on an ironclad, CPA-led EBITDA analysis and practice valuation.<\/em><\/figcaption><\/figure>\n<p>Key inputs include 3 years of tax returns, profit-and-loss statements, production reports by provider, hygiene revenue as a percentage of total collections, and a full schedule of owner add-backs such as personal expenses, above-market owner compensation, and one-time costs.<\/p>\n<p>The gap between a buyer-generated \u201cfree\u201d valuation and a diligence-grade analysis can be substantial. Practices that qualify for DSO acquisition can command <a target=\"_blank\" rel=\"noindex nofollow\" href=\"https:\/\/privatepracticeresearch.org\/reports\/baseline-2026\">premiums over traditional private-buyer valuations<\/a>. Those premiums tend to hold only when the EBITDA analysis stands up to scrutiny. A weak analysis often gets renegotiated down during diligence after the owner has already invested months in the process.<\/p>\n<h2>Step 2: Use a 10-Factor Checklist for Every Offer<\/h2>\n<p>Once EBITDA is established, you can evaluate every offer across the same 10 factors. This creates an apples-to-apples comparison instead of focusing on a single headline number.<\/p>\n<p>The table below provides a framework for side-by-side review. Specific values can vary by practice and buyer. The ranges reflect 2026 market data and dentists may want to verify them against specific offers with qualified advisors.<\/p>\n<table style=\"min-width: 75px;\">\n<colgroup>\n<col style=\"min-width: 25px;\">\n<col style=\"min-width: 25px;\">\n<col style=\"min-width: 25px;\"><\/colgroup>\n<tbody>\n<tr>\n<th colspan=\"1\" rowspan=\"1\">\n<p>Factor<\/p>\n<\/th>\n<th colspan=\"1\" rowspan=\"1\">\n<p>What to Look For<\/p>\n<\/th>\n<th colspan=\"1\" rowspan=\"1\">\n<p>Red Flags<\/p>\n<\/th>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Cash-at-close %<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Typically 60\u201380% of headline value<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Below 60% without strong equity upside<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Equity structure &amp; liquidity<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>JV-level (distributions, lower ceiling) vs. HoldCo (higher ceiling, no distributions); rollover typically 15\u201340% of proceeds<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>No tag-along rights, no information rights, no anti-dilution provisions<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Earnout terms<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>24-month duration most common, with pro-rata (linear) payout preferred<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>All-or-nothing triggers, or metrics the seller cannot control post-close<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Management fees<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Typically a percentage of revenue, and must be fair market value under California MSO rules<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Fees that vary based on practice profitability, which are prohibited under the Aspen settlement<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Clinical autonomy<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Written protections for treatment planning, scheduling, and staffing decisions<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Quotas, production incentives for hygienists, or DSO control over billing and coding<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Staff retention<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Named staff protections and associate employment agreement terms reviewed pre-close<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>No staff commitments, or associate re-signing required only at the buyer\u2019s discretion<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Post-close support<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Specific commitments on HR, IT, compliance, and marketing infrastructure<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Vague \u201csupport\u201d language with no defined service levels<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Buyer&#8217;s track record<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>References from sellers 3+ years post-close, plus PE backer stability and hold-period stage<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>DSOs whose internal shares have been marked to zero<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>California regulatory compliance<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>MSO agreement reviewed for SB 351 compliance, with no replacement-rights clauses<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Revenue-based management fees or DSO control over hiring and firing clinical staff<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Total after-tax proceeds (3\/5\/7\/10 years)<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Modeled across all components with capital-gains vs. ordinary-income allocation<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Headline number only, with no multi-year cash-flow model provided<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Step 3: Benchmark 2026 Multiples for Your Size and Region<\/h2>\n<p>The 10-factor checklist gives you a structure for comparing offers. Those comparisons become more meaningful when you anchor them to realistic valuation ranges for your practice type and location.<\/p>\n<p>California practices can vary in value by region and market type. The ranges below reflect 2026 market data and are directional. Your specific multiple can depend on EBITDA quality, owner dependence, hygiene contribution, payer mix, and lease terms. These benchmarks show how valuation multiples often increase with practice size and platform characteristics.<\/p>\n<ul>\n<li>\n<p><strong>Single-location dental practices under $1M EBITDA:<\/strong> often trade at approximately 5x\u20137x EBITDA for established practices with stable hygiene. Multiples can be lower for owner-dependent practices with cleanup needs.<\/p>\n<\/li>\n<li>\n<p><strong>Multi-location dental platforms with $1M+ EBITDA:<\/strong> <a target=\"_blank\" rel=\"noindex nofollow\" href=\"https:\/\/www.thesorso.com\/answers\/dso-acquisition-multiples\">commonly trade around 8x\u201311x EBITDA (or 7x\u20139x for $1M\u2013$3M associate-led groups)<\/a>.<\/p>\n<\/li>\n<li>\n<p><strong>Emerging platform, $3M\u2013$5M EBITDA:<\/strong> can achieve 9x\u201311x EBITDA for platform-grade transactions.<\/p>\n<\/li>\n<li>\n<p><strong>Specialty practices (orthodontics, oral surgery, pediatric, periodontics):<\/strong> can trade at higher EBITDA multiples than general practices, reflecting higher margins and referral stability.<\/p>\n<\/li>\n<\/ul>\n<p>Multiple suppressors that can reduce valuations can include <a target=\"_blank\" rel=\"noindex nofollow\" href=\"https:\/\/thesorso.com\/answers\/dental-practice-ebitda-multiple\">Medicaid revenue above 40% of collections, one provider responsible for more than 40% of production, and lease terms with under 5 years remaining<\/a>.<\/p>\n<h2>Step 4: Evaluate DSO Buyers Like Long-Term Investments<\/h2>\n<p>When up to 40% of a DSO deal is paid in equity instead of cash, the selling dentist effectively becomes an investor in the DSO platform.<\/p>\n<p>Some DSOs have informed their partners that internal shares currently hold zero value, which reflects missed recapitalization expectations. This history makes buyer selection a financial decision, not just a cultural one.<\/p>\n<p>Before accepting any offer, many owners review the buyer on these dimensions:<\/p>\n<ul>\n<li>\n<p>Whether the PE backer is well-capitalized and experienced in dental, for example Heartland Dental with KKR and Ontario Teachers\u2019 Pension Plan, or MB2 Dental with Charlesbank Capital Partners and Warburg Pincus.<\/p>\n<\/li>\n<li>\n<p>Where the PE fund sits in its hold period. Most surveyed DSOs anticipate recapitalization within 12 to 36 months, and a near-term event can be favorable for equity holders.<\/p>\n<\/li>\n<li>\n<p>Whether the DSO\u2019s existing portfolio grows revenue and EBITDA at the office level, not just through acquisitions.<\/p>\n<\/li>\n<li>\n<p>Whether the DSO has a documented track record of satisfied sellers in California specifically.<\/p>\n<\/li>\n<\/ul>\n<h2>Step 5: Use a Competitive, Auction-Style Sale Process<\/h2>\n<p>A competitive process with multiple bidders can materially change your outcome. <a target=\"_blank\" rel=\"noindex nofollow\" href=\"https:\/\/privatepracticeresearch.org\/reports\/marketed-process-premium\">Multi-bid processes across at least 3 DSO buyers can produce final offers around 50% above single-bid baselines<\/a>, with professional transition advisors often adding further uplift when they manage the process.<\/p>\n<p>Sellers in structured competitive processes average 5 or more offers, with final transaction values significantly above initial offers.<\/p>\n<p>A structured process typically runs 45\u201360 days from go-to-market to initial offers. It often includes a virtual data room, a marketing deck, and simultaneous outreach to a vetted buyer pool. Single-bid outcomes give the buyer full negotiating leverage and little reason to improve terms.<\/p>\n<h2>Step 6: Compare After-Tax Cash Flows, Not Just Multiples<\/h2>\n<p>Headline multiples rarely match what you keep after taxes and employment commitments. A side-by-side cash-flow model can clarify the real difference between offers.<\/p>\n<p>The table below illustrates a hypothetical comparison framework for a California general practice with $1.8M in collections and $360,000 in normalized EBITDA. These figures are illustrative only and do not represent a valuation or projection for any specific practice.<\/p>\n<table style=\"min-width: 75px;\">\n<colgroup>\n<col style=\"min-width: 25px;\">\n<col style=\"min-width: 25px;\">\n<col style=\"min-width: 25px;\"><\/colgroup>\n<tbody>\n<tr>\n<th colspan=\"1\" rowspan=\"1\">\n<p>Metric<\/p>\n<\/th>\n<th colspan=\"1\" rowspan=\"1\">\n<p>Offer A (Single-Bid DSO)<\/p>\n<\/th>\n<th colspan=\"1\" rowspan=\"1\">\n<p>Offer B (Competitive Process DSO)<\/p>\n<\/th>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Headline value (6x vs. 7.5x EBITDA)<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>$2,160,000<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>$2,700,000<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Cash at close (65% vs. 70%)<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>$1,404,000<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>$1,890,000<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Rollover equity (25%)<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>$540,000 (illiquid 3\u20137 yrs)<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>$675,000 (illiquid 3\u20137 yrs)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Earnout (10%, 24-month)<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>$216,000 (contingent)<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>$135,000 (contingent, pro-rata)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Est. tax impact (LTCG vs. ordinary income allocation)<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Higher ordinary income allocation<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Negotiated LTCG-favorable allocation<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"1\" rowspan=\"1\">\n<p>Employment comp gap (est. $75K\/yr \u00d7 4 yrs)<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>\u2013$300,000<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\n<p>\u2013$200,000 (shorter term negotiated)<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The difference between a single-bid and a competitive outcome on a practice of this size can exceed $500,000 in realized after-tax proceeds over a 5-year horizon, before equity rollover performance. <a target=\"_blank\" rel=\"noindex nofollow\" href=\"https:\/\/privatepracticeresearch.org\/reports\/is-your-dso-offer-fair\">DSO sales typically allocate 15\u201325% more of total proceeds to consulting and employment agreements with ordinary income treatment than internal sales<\/a>. This shift moves dollars from long-term capital gains rates to ordinary income rates of 32\u201337%, which many owners choose to model explicitly.<\/p>\n<h2>Step 7: Shape LOI Terms and Protect Value in Diligence<\/h2>\n<p>The LOI is where total economics are largely set, so focused negotiation here can pay off later.<\/p>\n<p>Key negotiation points fall into three categories. First, protect contingent value by pushing for pro-rata earnout provisions so a near-miss on an EBITDA target still pays most of the earnout, and by negotiating a later earnout start date that accounts for integration disruption. Second, secure your equity position by obtaining tag-along rights, quarterly information rights, and anti-dilution protections on rollover equity. Third, lock in the financial and regulatory framework by fixing expense allocations used in EBITDA calculations post-close and confirming that management fees are structured as fair-market-value service fees compliant with California\u2019s SB 351 and the May 2026 Aspen Dental settlement framework.<\/p>\n<p>After LOI signing, the buyer\u2019s quality-of-earnings team will scrutinize every add-back. The diligence-grade EBITDA analysis described in Step 1 is the primary defense against the re-trading risk outlined earlier. Reminding buyers that other vetted bidders remain in the process can also help maintain headline value.<\/p>\n<p><a target=\"_blank\" rel=\"noopener noreferrer nofollow\" href=\"https:\/\/dentaltransitions.com\/contact-us\/\"><strong>Schedule a free, confidential discovery call with McLerran &amp; Associates<\/strong><\/a> to get a diligence-grade EBITDA analysis and side-by-side offer comparison before you sign any LOI.<\/p>\n<figure style=\"text-align: center;\"><img src=\"https:\/\/cdn.aigrowthmarketer.co\/1782231776232-426cf610db07.jpeg\" alt=\"A chat at McLerran &amp; Associates: the dental-specific sell-side advisor and advocate for practice owners guides on how, when, and to whom to sell your practice.\" style=\"max-height: 500px;\" loading=\"lazy\" decoding=\"async\"><figcaption><em>A chat at McLerran &amp; Associates: the dental-specific sell-side advisor and advocate for practice owners guides on how, when, and to whom to sell your practice.<\/em><\/figcaption><\/figure>\n<h2>Trade-Offs of Affiliating With a DSO<\/h2>\n<p>DSO affiliation can create meaningful benefits and also real trade-offs that owners may want to weigh carefully.<\/p>\n<ul>\n<li>\n<p><strong>Reduced autonomy over non-clinical operations:<\/strong> Scheduling, billing, supply contracts, and branding typically migrate to the DSO\u2019s platform model within the first 12\u201324 months post-close.<\/p>\n<\/li>\n<li>\n<p><strong>Post-close employment commitment:<\/strong> Buyers typically require a minimum 5-year post-close employment term, with compensation often structured at 25\u201330% of collections instead of owner distributions.<\/p>\n<\/li>\n<li>\n<p><strong>Contingent proceeds:<\/strong> Roughly 20\u201340% of DSO deal value is often tied to earnouts and equity rollovers that can take 1\u20137 years to materialize.<\/p>\n<\/li>\n<li>\n<p><strong>Equity risk:<\/strong> Rollover equity is illiquid, and its value depends on the DSO platform\u2019s performance and the PE backer\u2019s eventual exit.<\/p>\n<\/li>\n<li>\n<p><strong>California regulatory complexity:<\/strong> SB 351 and the Aspen Dental settlement create compliance obligations that poorly structured deals may violate, which can expose both parties to enforcement risk.<\/p>\n<\/li>\n<\/ul>\n<h2>When DSO Affiliation Can Make Sense<\/h2>\n<p>For California practices generating $1.5M or more in revenue, DSO affiliation can be attractive when the owner\u2019s goals match the structure being offered.<\/p>\n<p>Affiliation tends to fit when an owner wants to take significant capital off the table, access infrastructure for growth, reduce the burden of running the business, or plan a phased exit over 3\u20135 years. It tends to fit less when the owner wants a clean, fast exit, has a practice below typical DSO qualification thresholds, or places high value on day-to-day operational independence.<\/p>\n<p>A clear answer usually comes from a side-by-side comparison of the DSO path against the private-buyer path. That comparison quantifies what the practice may be worth in both markets before the owner chooses a direction. Because McLerran &amp; Associates works both paths in roughly equal measure, the firm can present that comparison rather than steering owners toward a single lane.<\/p>\n<h2>California Rules That Shape Every DSO Deal<\/h2>\n<p>California is one of the most regulated states for DSO transactions. Every offer received by a California practice owner can be reviewed against the following framework.<\/p>\n<ul>\n<li>\n<p><strong>SB 351 (effective January 1, 2026):<\/strong> Prohibits private equity-backed DSOs and MSOs from interfering with clinical judgment, controlling billing and coding, setting patient volume quotas, hiring or firing dentists or clinical staff, or selecting medical equipment. Contract terms that violate these limits are void and unenforceable.<\/p>\n<\/li>\n<li>\n<p><strong>Corporate Practice of Dentistry (CPOD):<\/strong> Professional corporations for dentistry must be formed under the Moscone-Knox Professional Corporation Act, which requires all owners, directors, and officers to be licensed California dentists. Non-dentists may participate financially through MSOs but cannot own the dental practice or control clinical decisions.<\/p>\n<\/li>\n<li>\n<p><strong>Aspen Dental Settlement (May 2026):<\/strong> <a target=\"_blank\" rel=\"noindex nofollow\" href=\"https:\/\/oag.ca.gov\/news\/press-releases\/attorney-general-bonta-announces-settlement-aspen-dental-over-corporate-practice\">The California Attorney General imposed $2 million in civil penalties along with $300,000 in restitution and injunctive terms<\/a>, creating a detailed compliance framework for DSOs in California. Management fees must not vary based on practice profitability.<\/p>\n<\/li>\n<li>\n<p><strong>AB 1415:<\/strong> Effective January 1, 2026, this law generally requires 90-day advance notice to the Office of Health Care Affordability for healthcare transactions involving MSOs, PE investors, and dental practice affiliations. This requirement adds a mandatory review timeline to California DSO deals.<\/p>\n<\/li>\n<li>\n<p><strong>Non-compete enforceability:<\/strong> In California, where non-compete enforceability is weaker, buyers often rely on earnouts and non-solicit provisions instead. This reality can affect how earnout terms are written and negotiated.<\/p>\n<\/li>\n<\/ul>\n<h2>Common Deal Challenges and Practical Fixes<\/h2>\n<ul>\n<li>\n<p><strong>Valuation gap:<\/strong> The owner expects peak 2021 pricing while the buyer offers 2026 market rates. Fix: anchor expectations to a diligence-grade EBITDA analysis and a competitive process that reveals current market value.<\/p>\n<\/li>\n<li>\n<p><strong>Incomplete financials:<\/strong> Missing add-back documentation reduces EBITDA and suppresses the offer. Fix: prepare a full add-back schedule before going to market.<\/p>\n<\/li>\n<li>\n<p><strong>Buyer-fit concerns:<\/strong> The highest bidder may not be the right long-term partner. Fix: vet buyers on track record, PE backer stability, and post-close support commitments, not just headline price.<\/p>\n<\/li>\n<li>\n<p><strong>Diligence pushback:<\/strong> The buyer\u2019s quality-of-earnings team challenges add-backs after LOI. Fix: complete diligence-grade work up front, with every add-back documented and defensible before the deal goes out.<\/p>\n<\/li>\n<li>\n<p><strong>California compliance risk:<\/strong> The MSO agreement contains provisions prohibited under SB 351 or the Aspen framework. Fix: have California-experienced legal counsel review the management agreement before LOI signing.<\/p>\n<\/li>\n<\/ul>\n<h2>How to Measure a Successful DSO Sale<\/h2>\n<p>A successful DSO transaction for a California practice owner can be measured against several objective indicators.<\/p>\n<ul>\n<li>\n<p>Valuation quality: Did the EBITDA analysis hold through diligence without renegotiation?<\/p>\n<\/li>\n<li>\n<p>Number of offers: Did the process generate multiple competitive bids?<\/p>\n<\/li>\n<li>\n<p>Timeline: Did the deal close within a reasonable window without unnecessary delays?<\/p>\n<\/li>\n<li>\n<p>Staff retention: Are key staff and associates still in place 90 days post-close?<\/p>\n<\/li>\n<li>\n<p>Goal alignment: Does the buyer\u2019s structure, support model, and culture match what the owner wanted for the practice?<\/p>\n<\/li>\n<li>\n<p>After-tax proceeds: Do realized proceeds across cash, earnout, and equity match or exceed the modeled projection?<\/p>\n<\/li>\n<\/ul>\n<h2>Advanced Strategies for Growing Future Practice Value<\/h2>\n<p>Owners who are not yet ready to transact can still benefit from periodic readiness assessments. Practices that add one producing associate dentist can increase valuation by approximately one full turn of EBITDA, because collections become more transferable after the owner exits, according to Vallexa Advisors citing FOCUS Investment Banking and Auxo Capital dental valuation reporting.<\/p>\n<p>Phased exits are increasingly common. In these structures, an owner sells a majority stake now and retains equity for a second liquidity event at recapitalization. Given that most DSOs expect near-term recapitalization, as noted in Step 4, the timing of equity rollover becomes a live consideration in 2026 deal structuring.<\/p>\n<p>For the largest California practices, especially those approaching or exceeding $2.5M in EBITDA, the practice itself can sometimes become the platform acquisition of a new DSO. In those cases, the owner may step in as CEO and capture higher valuation multiples than a sale into an existing platform might provide.<\/p>\n<h2>Next Step: Get Side-by-Side Valuations and Forecasts<\/h2>\n<p>Receiving one or two DSO offers without a structured comparison process can leave real money, deal certainty, and legacy protection on the table.<\/p>\n<p>The seven steps above, anchored by a diligence-grade EBITDA analysis and a competitive process among vetted buyers, give California practice owners a framework to see likely after-tax proceeds and choose the right fit.<\/p>\n<p>McLerran &amp; Associates has guided owners through roughly 2,000 successful practice sales and approximately $2 billion in closed transaction volume, working both the private-buyer and DSO paths in roughly equal measure. The firm\u2019s Los Angeles office, led by Steven Au, works directly with California practice owners navigating the state\u2019s regulatory environment and buyer landscape.<\/p>\n<figure style=\"text-align: center;\"><img src=\"https:\/\/cdn.aigrowthmarketer.co\/1782231581955-2aa75d9d4697.jpeg\" alt=\"McLerran &amp; Associates team: McLerran is the nation's largest dental-specific sell-side M&amp;A advisory and brokerage firms\" style=\"max-height: 500px;\" loading=\"lazy\" decoding=\"async\"><figcaption><em>McLerran &amp; Associates team: McLerran is the nation&#8217;s largest dental-specific sell-side M&amp;A advisory and brokerage firms<\/em><\/figcaption><\/figure>\n<p><a target=\"_blank\" rel=\"noopener noreferrer nofollow\" href=\"https:\/\/dentaltransitions.com\/contact-us\/\"><strong>Schedule a free, confidential discovery call with McLerran &amp; Associates<\/strong><\/a> to receive a comprehensive, CPA-led EBITDA analysis, a side-by-side valuation in both the private-buyer and DSO markets, and multi-year cash-flow modeling across deal structures before you respond to any offer. Call (512) 900-7989, email info@dentaltransitions.com, or visit dentaltransitions.com\/contact-us.<\/p>\n<h2>Frequently Asked Questions<\/h2>\n<h3>How can I tell if a DSO offer for my California practice is fair?<\/h3>\n<p>A DSO offer can usually be evaluated as fair or unfair only in relation to an independent, diligence-grade EBITDA analysis and the full range of offers available in the market. A single offer with no independent valuation gives the buyer control over the anchor number. Many owners find that a structured, competitive process that generates multiple bids from vetted buyers at the same time creates the leverage needed to move terms toward best-and-final. In California, fairness also involves reviewing the offer\u2019s management agreement structure against SB 351 and the Aspen Dental settlement framework to confirm that fee arrangements and control provisions appear legally compliant.<\/p>\n<h3>What is the difference between JV-level equity and holding-company equity in a DSO deal?<\/h3>\n<p>Joint-venture (JV) equity is ownership at the individual practice level within the DSO\u2019s structure. It usually comes with ongoing distributions, meaning a share of that specific practice\u2019s profits, which can give the owner a higher income floor during the post-close employment period. The upside, however, is limited to that practice\u2019s performance.<\/p>\n<p>Holding-company (HoldCo) equity is ownership in the overall DSO platform. It typically carries no distributions during the hold period, so the owner receives no income from that equity until the platform recapitalizes or sells. The upside potential can be higher, because strong platform performance may increase value significantly, but the risk is also higher, since value depends on the DSO\u2019s enterprise performance and the PE backer\u2019s exit execution. Understanding which type of equity is being offered, and at what percentage of total deal value, can be essential before comparing two offers that appear similar on headline price.<\/p>\n<h3>How does California\u2019s SB 351 affect a DSO affiliation deal?<\/h3>\n<p>SB 351, effective January 1, 2026, codifies and expands California\u2019s corporate practice of dentistry prohibitions that specifically target private equity-backed DSOs and MSOs. In practical terms, any management or employment agreement in a California DSO deal may need review to confirm it does not grant the DSO control over clinical judgment, billing and coding decisions, patient volume quotas, hiring or firing of dentists or clinical staff, or selection of medical equipment.<\/p>\n<p>Contract terms that violate SB 351 are void and unenforceable, which can create deal risk if the agreement is not structured correctly from the outset. The May 2026 Aspen Dental settlement with the California Attorney General added further specificity by prohibiting revenue-based management fees and requiring DSOs to register with the Dental Board of California. Many owners choose to engage California-experienced legal counsel to review any LOI and management agreement before signing.<\/p>\n<h3>What happens if a DSO deal violates California regulations?<\/h3>\n<p>If a DSO deal violates California regulations such as SB 351 or the terms established by the Aspen Dental settlement, the offending contract provisions are typically void and unenforceable. This situation can create significant deal risk, including potential regulatory penalties, required deal restructuring, or even termination.<\/p>\n<p>To reduce this risk, many owners work with California-experienced legal counsel to review any LOI and management agreement before signing, so that the structure aligns with applicable rules.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>DSO opening offers can run 15\u201325% below final. McLerran helps CA dentists compare payout structures, equity models, and autonomy terms. Get started.<\/p>\n","protected":false},"author":1,"featured_media":103,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-104","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/posts\/104","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/comments?post=104"}],"version-history":[{"count":1,"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/posts\/104\/revisions"}],"predecessor-version":[{"id":110,"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/posts\/104\/revisions\/110"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/media\/103"}],"wp:attachment":[{"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/media?parent=104"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/categories?post=104"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/tags?post=104"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}